Should I buy or sell BioTelemetry stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BEAT shares. View BEAT analyst ratings or view top-rated stocks .

What is BioTelemetry's stock price target for 2024?

1 Wall Street analysts have issued 12-month target prices for BioTelemetry's shares. Their BEAT share price targets range from $5.55 to $8.00. On average, they expect the company's share price to reach $6.78 in the next year. This suggests a possible upside of 251.0% from the stock's current price. View analysts price targets for BEAT or view top-rated stocks among Wall Street analysts .

Are investors shorting BioTelemetry?

BioTelemetry saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 159,400 shares, an increase of 20.7% from the March 15th total of 132,100 shares. Based on an average daily trading volume, of 133,400 shares, the short-interest ratio is presently 1.2 days. Currently, 0.8% of the shares of the company are sold short. View BioTelemetry's Short Interest .

When is BioTelemetry's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BEAT earnings forecast .

How were BioTelemetry's earnings last quarter?

BioTelemetry, Inc. (NASDAQ:BEAT) announced its quarterly earnings results on Wednesday, March, 20th. The medical research company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. During the same period in the previous year, the firm posted ($0.45) earnings per share.

What is Joseph H. (Joe) Capper's approval rating as BioTelemetry's CEO?

40 employees have rated BioTelemetry Chief Executive Officer Joseph H. (Joe) Capper on Glassdoor.com . Joseph H. (Joe) Capper has an approval rating of 53% among the company's employees. This puts Joseph H. (Joe) Capper in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Block (SQ) , AT&T (T) , AbbVie (ABBV) , Alibaba Group (BABA) , Netflix (NFLX) and Gilead Sciences (GILD) .

When did BioTelemetry IPO?

BioTelemetry (BEAT) raised $16 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 2,750,000 shares at $5.50-$6.50 per share.

NASDAQ:BEAT

BioTelemetry (BEAT) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free BEAT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.93
▼
$2.16
50-Day Range: $71.46
▼
$72.27
52-Week Range: $27.35
▼
$73.10

Volume: 79,498 shs
Average Volume: 86,804 shs
Market Capitalization: $50.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.78

Stock Analysis Analyst Forecasts Competitors Earnings Headlines Insider Trades Short Interest Social Media

Get BioTelemetry alerts:

BioTelemetry MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 251.0% Upside
$6.78 Price Target
Short Interest: Healthy
0.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.71 out of 5 stars

Medical Sector

846th out of 911 stocks

Surgical & Medical Instruments Industry

88th out of 97 stocks

3.5

Analyst's Opinion

Consensus Rating
BioTelemetry has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
BioTelemetry has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.82% of the float of BioTelemetry has been sold short.
Short Interest Ratio / Days to Cover
BioTelemetry has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioTelemetry has recently increased by 20.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioTelemetry does not currently pay a dividend.
Dividend Growth
BioTelemetry does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BEAT.

0.0

News and Social Media Coverage

Search Interest
Only 8 people have searched for BEAT on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioTelemetry insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.32% of the stock of BioTelemetry is held by insiders.
Percentage Held by Institutions
Only 7.77% of the stock of BioTelemetry is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of BioTelemetry is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioTelemetry is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioTelemetry has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About BioTelemetry Stock (NASDAQ:BEAT)

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

BEAT Stock News Headlines

April 9, 2024 | businesswire.com

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

March 21, 2024 | finance.yahoo.com

HeartBeam, Inc. (NASDAQ:BEAT) Q4 2023 Earnings Call Transcript

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 20, 2024 | investorplace.com

BEAT Stock Earnings: HeartBeam Meets EPS for Q4 2023

March 14, 2024 | businesswire.com

First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo™ System for Synthesizing a 12-Lead ECG

March 7, 2024 | businesswire.com

HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology

January 31, 2024 | usatoday.com

Kelce scores twice and Chiefs beat Bills 27-24 to advance to face Ravens in AFC championship

January 6, 2024 | foxnews.com

Boy, 13, becomes first documented player to beat Tetris

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

December 28, 2023 | finance.yahoo.com

Insiders Of HeartBeam Are Up 49% On Their US$2.89m Purchase

December 20, 2023 | bbc.com

Can football-playing robots beat the World Cup winners by 2050?

December 2, 2023 | bbc.co.uk

NFL: Philadelphia Eagles come from behind to beat Kansas City Chiefs

November 21, 2023 | bbc.com

SWPL: Watch the goals as Hibernian beat Hearts to retain the Capital Cup

November 21, 2023 | foxnews.com

Las Vegas teens who beat 17-year-old student to death near high school facing murder charges

November 15, 2023 | finance.yahoo.com

HeartBeam, Inc. (NASDAQ:BEAT) Q3 2023 Earnings Call Transcript

November 15, 2023 | usatoday.com

If Diamondbacks beat Phillies in NLCS, sports talk host Chris Russo says he will retire

November 11, 2023 | morningstar.com

HeartBeam Inc BEAT

October 27, 2023 | foxnews.com

Steelers fight back from fourth-quarter deficit to beat Rams

October 13, 2023 | abcnews.go.com

GOP megadonors tell DeSantis and Haley: Pitch us on how you can beat Trump

October 7, 2023 | usatoday.com

Texans look to build on first win after putting everything together to beat Jaguars

October 7, 2023 | cnn.com

Exclusive: Hillary Clinton says Trump is likely GOP 2024 nominee but Biden can still beat him

September 17, 2023 | foxnews.com

Colorado's Deion Sanders says son, Shedeur, had extra motivation to beat TCU after coach's past disrespect

September 17, 2023 | nypost.com

Heartless husband who beat wife to death at NYC bus stop sentenced as daughter rips him in court: ‘I hope you rot in prison’

July 21, 2023 | finance.yahoo.com

This HeartBeam Insider Increased Their Holding By 2,769% Last Year

June 18, 2023 | latimes.com

Column: Here’s Trump’s outlandish and dangerous plan to beat the classified documents case

June 8, 2023 | finance.yahoo.com

HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors

May 23, 2023 | thestreet.com

Why BioTelemetry (BEAT) Is Soaring Today

See More Headlines

Receive BEAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioTelemetry and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:BEAT
CUSIP: N/A
CIK: 1574774
Web: www.gobio.com
Phone: 610-729-7000
Fax: N/A
Employees: 1,700
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.78
High Stock Price Target: $8.00
Low Stock Price Target: $5.55
Potential Upside/Downside: +251.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -106.91%
Return on Assets: -97.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.09
Quick Ratio: 14.09

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.61 per share
Price / Book: 3.16

Miscellaneous

Outstanding Shares: 26,330,000
Free Float: 24,402,000
Market Cap: $50.82 million
Optionable: Not Optionable
Beta: -1.22

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Joseph H. Capper (Age 57)
CEO, Pres & Director
Comp: $1.21M
Ms. Heather C. Getz (Age 46)
Exec. VP, CFO & Chief Admin. Officer
Comp: $616.68k
Mr. Fred Broadway III (Age 51)
Pres of BioTel Heart
Comp: $524.63k
Mr. Daniel M. Wisniewski (Age 57)
Sr. VP of Technical Operations
Comp: $506.54k
Dr. Andrei G. Stoica
Chief Technology Officer
Cody Cowper
VP of Legal & Corp. Sec.
Amy M. Knapp
Vice president of Corp. Communications
Mr. Tim Raher
Sr. VP of HR
Dr. Peter R. Kowey
Medical Director and Chairman of Medical Advisory Board
Mr. Scott Satin
Pres & GM of BioTel Research

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

BEAT Stock Analysis - Frequently Asked Questions

Should I buy or sell BioTelemetry stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BEAT shares.
View BEAT analyst ratings or view top-rated stocks.
What is BioTelemetry's stock price target for 2024?: 1 Wall Street analysts have issued 12-month target prices for BioTelemetry's shares. Their BEAT share price targets range from $5.55 to $8.00. On average, they expect the company's share price to reach $6.78 in the next year. This suggests a possible upside of 251.0% from the stock's current price.
View analysts price targets for BEAT or view top-rated stocks among Wall Street analysts.
Are investors shorting BioTelemetry?: BioTelemetry saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 159,400 shares, an increase of 20.7% from the March 15th total of 132,100 shares. Based on an average daily trading volume, of 133,400 shares, the short-interest ratio is presently 1.2 days. Currently, 0.8% of the shares of the company are sold short.
View BioTelemetry's Short Interest.
When is BioTelemetry's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BEAT earnings forecast.

How were BioTelemetry's earnings last quarter?: BioTelemetry, Inc. (NASDAQ:BEAT) announced its quarterly earnings results on Wednesday, March, 20th. The medical research company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. During the same period in the previous year, the firm posted ($0.45) earnings per share.
What is Joseph H. (Joe) Capper's approval rating as BioTelemetry's CEO?: 40 employees have rated BioTelemetry Chief Executive Officer Joseph H. (Joe) Capper on Glassdoor.com. Joseph H. (Joe) Capper has an approval rating of 53% among the company's employees. This puts Joseph H. (Joe) Capper in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of BioTelemetry own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Netflix (NFLX) and Gilead Sciences (GILD).
When did BioTelemetry IPO?: BioTelemetry (BEAT) raised $16 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 2,750,000 shares at $5.50-$6.50 per share.

This page (NASDAQ:BEAT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioTelemetry (BEAT) Stock Price, News & Analysis

BioTelemetry MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About BioTelemetry Stock (NASDAQ:BEAT)

BEAT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

BEAT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™